ORKAMBI reimbursement established in Germany

|By:, SA News Editor

Vertex Pharmaceuticals (NASDAQ:VRTX) inks a pricing and reimbursement agreement with the German Federal Association of the Statutory Health Insurances for ORKAMBI (lumacaftor/ivacaftor), approved by the European Commission in November 2015.

The agreement took effect on Friday, December 16.

Subscribe for full text news in your inbox